Cardiac hypertrophy/remodeling manifests as a critical condition which may likely predispose to the risk of
fatal heart failure and multiple organ dysfunction if not efficiently addressed, as a result of irreversible neuroendocrine,
autonomic and immune system imbalances. Undeniably, the over-excitation of sympathetic and/or the breakdown of
central parasympathetic tone play a significant role to be the basis of the persistent immune activation in chronic heart
failure (CHF) which, to a certain extent, is primed by inflammatory reactions in the Central Nervous System. Moreover,
till today, the clinical management of CHF seeks the identification of molecularly targeted drugs in comparison to those
considered so far. This review focuses on the possible neuroimmune-mediated pathways involved in CHF and throws
light on the current therapeutic strategies.